Thus, in the context of asthma therapy, the blockade of NF-κB translocation and of RANKL/RANK interaction seems to have a certain advantage over: (a) the blockade of IKK with regard to the inhibitory effect on IL-4 and IL-17 production in Th2 and Th17 cells, respectively; (b) glucocorticosteroids with regard to the inhibitory effect on IL-4 production in Th2 cells. The gene discussed is IL4; the disease is asthma.